Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

23 June 2020: Clinical Research  

The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis

Mei Tian1BE, Xiuchun Yang1CD, Yanfang Li1BF, Sen Guo2ABCDEFG*

DOI: 10.12659/MSM.923359

Med Sci Monit 2020; 26:e923359



BACKGROUND: The classical dynamin family consists of dynamin 1, 2, and 3, which have different expression levels in different tissues to regulate cell membrane fission and endocytosis. Recent studies have reported increased expression of dynamins in human cancer, but their expression in hepatocellular carcinoma (HCC) remains to be determined. This study aimed to investigate the expression of dynamin 1, 2, and 3 in tissue sections of human HCC using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry.

MATERIAL AND METHODS: The expression of dynamin 1, 2, and 3 were investigated in 192 cases of HCC and 14 paired samples of HCC and adjacent normal liver tissue by qRT-PCR and immunohistochemistry. The clinical significance of dynamin 1, 2, and 3 were determined by correlating their expression levels with patient clinicopathological factors and survival rates. Independent prognostic factors were determined using the Cox regression hazard model.

RESULTS: In tissue samples from 192 patients with HCC, the expression of dynamin 1, 2, and 3 were upregulated in 41.15%, 29.69%, and 8.33% of cases, respectively. Dynamin 1 had a significantly increased mRNA expression level in HCC compared with adjacent normal liver tissues and was significantly correlated with alpha fetoprotein (AFP) levels, T stage, and TNM stage. Only dynamin 1 expression was correlated with the reduced overall survival (OS), and was identified as an independent prognostic biomarker of human HCC.

CONCLUSIONS: Upregulation of dynamin 1 at the protein and mRNA level was an independent prognostic biomarker of reduced OS in patients with HCC.

Keywords: Biological Markers, Carcinoma, Hepatocellular, Dynamin II, Prognosis, Dynamins, Gene Expression, Immunohistochemistry, Kaplan-Meier Estimate, Liver Neoplasms, Middle Aged, Neoplasm Staging, Proportional Hazards Models, transcriptome, alpha-Fetoproteins


Worldwide, primary liver cancer is the fifth most common malignancy [1]. Hepatocellular carcinoma (HCC) accounts for more than 90% of all primary liver cancers, with approximately 800,000 new cases annually [2]. The morbidity of HCC is increasing globally, with an increasing incidence from 1.5 to 4.9 per 100,000 individuals in the past 30 years [1]. The main causes of HCC include chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), alcohol abuse, and metabolic syndrome that is associated with diabetes and obesity [3].

Although there have been recent developments in targeted therapy for patients with HCC, including sorafenib and lenvatinib [4], the improvements in patient prognosis and overall survival (OS) following the use of these new drugs has been modest [5]. Even following radical surgery, the 5-year OS rate for patients with HCC is approximately 30% [6]. Because the prognosis of HCC remains poor, there is a need for new predictive and prognostic biomarkers for HCC.

Dynamin is a 96 kDa GTPase, and the classical dynamin family consists of dynamin 1, 2, and 3, which have different expression levels in different tissues to regulate cell membrane fission, endocytosis, and secretion of vesicles [7,8]. Dynamin consists of a GTPase domain, a middle domain, a GTPase effector domain, and a pleckstrin homology domain, which synergize to anchor membranes and hydrolyze GTP [9]. Dynamins 1 and 3 are mainly expressed in neural tissue, and dynamin 2 has a wide range of tissues [10]. However, recent studies have shown that dynamin 1 was upregulated in non-neuronal cells downstream of cancer-associated signaling pathways [11]. Although previous studies investigated the functions of dynamin in the regulation of endocytosis and secretion, there is increasing study data supporting the role of dynamin in the progression of human cancer, particularly dynamin 2 [12,13]. Ectopic expression of dynamin 1 and 2 have been shown in several types of cancers, including non-small cell lung cancer (NSCLC) and bladder cancer [12,13]. The expression of dynamin 1 and 2 have been shown to promote in vitro tumor cell migration in some specific malignant cell lines [14,15].

Therefore, this study aimed to investigate the expression of dynamin 1, 2, and 3 in tissue sections of human HCC using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry. The study also aimed to correlate the tissue expression of dynamin proteins and mRNA with clinicopathological factors and overall survival (OS) rates.

Material and Methods


Between 2009 and 2013, there were 345 patients with hepatocellular carcinoma (HCC) who were managed at the general surgery department of Qilu Hospital of Shandong University and Yidu Central Hospital, who provided the initial study cohort. From this cohort, 192 patients were selected who underwent radical surgery for HCC with clinical follow-up. There were 14 paired patient samples of HCC liver tissue with adjacent normal liver tissue that were collected and stored in liquid nitrogen from 2019.9. Fresh liver tissues were sampled during surgery, without affecting the procedures for tissue diagnosis. Tumor samples were taken from the non-necrotic areas of the tumor, and the normal adjacent liver tissue was sampled at least 1 cm away from the tumor.

All tissue samples were obtained with prior informed consent from the patients. The overall survival (OS) time was calculated from the time of surgery to death or final follow-up. There were no severe complications during the perioperative period, and all patients had a survival time more than two months after surgery. The tumor staging used was according to the 7th edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) TNM tumor staging system. The study was supervised and approved by the Ethics Committees of Qilu Hospital of Shandong University and Yidu Central Hospital, China.


The tissue microarrays (TMAs) were prepared, as previously reported, using formalin-fixed and paraffin-embedded tissue samples from the patients with HCC [16]. Hematoxylin and eosin (H&E) staining was performed on the routine tissue sections to assist in the identification of the location of the immunohistochemistry staining. Each case had two 1 mm arrays to improve the sampling accuracy.


Total RNA was extracted from fresh tissues using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s protocol. The qRT-PCR was performed with the PrimeScript RT reagent kit and SYBR Premix Ex Taq (Applied Biosystems, Waltham, MA, USA). The 2−ΔΔCt method was used to calculate the relative mRNA of Dynamin 1, with GAPDH as the internal control. The primers used in the study included:


The streptavidin peroxidase complex method was used to perform immunohistochemistry staining, according to previous studies [17,18]. Briefly, tissues were de-paraffinized and rehydrated using graded alcohol and xylene, and then incubated in 3% H2O2 to block endogenous peroxidase. Citrate buffer was used for optimal antigen retrieval, and 5% bovine serum albumin (BSA) was used to block nonspecific antibody binding. Primary antibodies were used at a dilution of 1: 200 to dynamin 1 (ab52611; Abcam, Cambridge, MA, USA), dynamin 2 (ab3457; Abcam, Cambridge, MA, USA), and dynamin 3 (PA1-662; Invitrogen, Carlsbad, CA, USA). Secondary antibodies and the streptavidin peroxidase complex were used (Sangon, Shanghai, China) followed by incubation in 3,3′-diaminobenzidine (DAB) solution (Sangon, Shanghai, China) to visualize the localization of the primary antibodies. The slides were counterstained with hematoxylin and mounted in resin.

Each tissue section was evaluated histologically by two pathologists who were unaware of the pathological data. The immunohistochemistry results were semi-quantified using a visual immunohistochemistry score that included the staining intensity and the percentage of immunopositive cells stained. The staining intensity scores were 0, 1, 2, and 3, which represented negative, weak, moderate, and strong immunostaining. The percentage scores of 1, 2, and 3 represented 0–25%, 25–50%, and >50% of positively immunostained cells. The final immunohistochemistry score was obtained by multiplying these two scores [19]. A combined immunohistochemistry score ≥4 was positive, and a score <4 was negative for the expression of dynamin isoforms by immunohistochemistry.


All data were analyzed with SPSS version 22.0 software (IBM, Chicago, IL, USA). The correlations between dynamin expression and clinicopathological factors were calculated using the chi-squared (χ2) test. The overall survival (OS) curves were calculated by the Kaplan-Meier method, and the statistical differences between the subgroups were evaluated with the log-rank test. The Cox proportional hazards regression model identified the independent prognostic parameters. P<0.05 was regarded as statistically significant.



This study included a consecutive cohort of 192 patients with hepatocellular carcinoma (HCC), with a mean postoperative follow-up of 38.2 months. The number of male patients was greater than female patients (173 vs. 19) (Table 1). Most patients with HCC had chronic hepatitis B virus (HBV) infection (73.96%), while only 6.77% of patients with HCC had hepatitis C virus (HCV) infection, which was consistent with the known strong association between HBV infection and HCC in China. There were 10.94% of patients who had intrahepatic metastasis (multiple tumor nodules), but only 1.04% of patients with HCC had lymphatic metastasis.


The expression of the three dynamin isoforms was detected by immunohistochemistry in the 192 HCC tissue specimens. Dynamin 1 and 3 were expressed in both the tumor cell cytoplasm and cell membrane, and dynamin 2 was mainly expressed in the cell membrane (Figure 1A–1C). Dynamin 1, was previously considered to be expressed in the nervous system and tumor tissue [11]. In this study, dynamin 1 had the highest expression in HCC among all the isoforms of dynamin, and was present in 41.15% of all HCCs. The upregulation of dynamin 2 and 3 was observed in 29.69% and 8.33% cases, respectively (Table 1). The mRNA levels of dynamin 1–3 were investigated in 14 tissue samples of HCC with paired adjacent normal liver tissues. The mRNA levels were standardized with adjacent liver tissues of dynamin 1 as 1.0. In this study, dynamin 2 had the highest mRNA expression levels in normal liver tissue, and dynamin 1 had the highest mRNA expression levels in HCC. Dynamin 1 mRNA was significantly upregulated in HCC compared with normal liver tissue (Figure 1D).


The clinicopathological significances of the expression of dynamin isoforms in the liver tissues were evaluated with the chi-squared (χ2) test to analyze their association with clinicopathological factors. The demographic factors included data on gender and age. The clinicopathological factors included data on the tumor size and tumor number, and the histopathological findings of vascular invasion, histological grade, tumor T stage, lymphatic metastasis, TNM stage. Clinical data included the presence of HBV and HCV infection and serum levels of alpha fetoprotein (AFP) (Table 2). Dynamin 1 expression was significantly associated with AFP, T stage, and TNM stage (P=0.001, 0.003, and 0.002, respectively). The overexpression of dynamin 1 was associated with high levels of AFP. Also, patients with high dynamin 1 expression showed an advanced T stage, indicating that dynamin 1 may promote tumor progression. There were no significant factors that were significantly associated with the expression of dynamin 2 and 3.


The prognostic significances of dynamin 1, 2, and 3, and other clinicopathological factors were initially analyzed using univariate analysis with the log-rank test (Table 3). The overall survival (OS) curves of low and high dynamin expression were identified using the Kaplan-Meier method. In the dynamin family, dynamin 1 was the only isoforms affecting the prognosis of patients with HCC. Patients with high expression of dynamin 1 had a worse prognosis than those with low expression of dynamin 1, with a 5-year OS rate of 58.4% compared with 34.0% (Figure 2A). However, dynamin 2 and 3 had no significant influence on the OS in this study (Figure 2A, 2B).

In the clinicopathological factors, patients with a large liver tumor size (P<0.001) and positive vascular invasion (P=0.001) had a poorer prognosis (Figure 3A, 3B). Advanced T stage (P<0.001) and TNM stage (P<0.001) were significant prognostic factors for patients with HCC (Figure 3C, 3D). Male patients had significantly lower OS rates compared with female patients (P=0.069).


The verified prognostic variables in the log-rank test were selected and analyzed by the Cox-regression model to identify the independent prognostic factors (Table 4). The prognostic factors with a P-value <0.5 underwent multivariate analysis and included the tumor size, vascular invasion, T stage, and dynamin 1 expression. TNM stage was excluded from the model because the above factors subsequently identified it. Dynamin 1 was verified as an independent prognostic biomarker of HCC (P=0.001; HR=2.06; 95% CI, 1.36–3.12). Also, T stage was identified as an independent prognostic factor (P<0.001; HR=2.9; 95% CI, 1.80–4.69). Tumor size was not confirmed to be an independent prognostic factor because it was one of the determinants of the T stage. Vascular invasion was an independent factor, but with low significance (P=0.060).


The aims of this study were to investigate the expression of dynamin 1, 2, and 3 in tissue sections of human hepatocellular carcinoma (HCC) using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, and to correlate the tissue expression of dynamin proteins and mRNA with clinicopathological factors and overall survival (OS) rates. Of the three members of the dynamin family studied, upregulation of dynamin 1 expression at the protein and mRNA level was an independent prognostic biomarker of reduced OS in patients with HCC.

Previous studies have shown that dynamin is a key protein in endocytosis, but the studies on carcinogenesis and cancer progression are limited. Recently published studies have shown that dynamins are capable of affecting many processes during tumor progression, including chemo-resistance, cell migration, and metastasis [14,20,21]. There have been some previous studies on the expression of dynamin in hepatocellular carcinoma (HCC). Sun et al. showed that mitochondrial fission promoted cell migration in HCC through the Ca2+/CaMKII/ERK/FAK pathway [22]. However, these authors did not investigate whether dynamin was involved in cancer progression as a key modulator of mitochondrial fission.

Previously reported studies have shown that the methylation of the dynamin 3 promoter was capable of downregulating its expression and was correlated with a worse prognosis in patients with HCC [23]. Also, dynamin 3 has previously been shown to reduce HCC tumor growth by activating P53 [24]. However, the down-regulation of dynamin 2 was previously reported to facilitate the invasion of HCC cells by promoting epidermal growth factor receptor (EGFR) signaling [25].

The three isoforms of dynamin have similar functions, but their expression varies in different tissues [26]. The findings from the present study showed that in HCC tissues, the expression of dynamin was dynamin 1 > dynamin 2 > dynamin 3. This study was the first to report the expression of all the dynamin isoforms with comparison in the same tumor cohort. Gong et al. showed that dynamin 2 was associated with poor prognosis in patients with HCC [25]. This previous finding differed with the findings from the present study, which found that dynamin 2 was not significantly associated with patient prognosis in HCC. This finding may be explained by the different cut-ff values used in the immunohistochemistry scoring systems. However, in the present study, a large study sample size was used, and dynamin 1 expression was confirmed in the cell membrane by immunohistochemistry, which was consistent with its function as a regulator of membrane fission and endocytosis.

Endocytosis is a fundamental process in all cells, including tumor cells. One important feature of tumor cells is the activated secretion of exosomes, which is regulated by endocytosis and endosomal sorting complexes required for transport (ESCRT) [27]. Dynamins have also been reported to have other functions in human cancers. For example, dynamin 2 was shown to stabilize filopodia in non-small cell lung carcinoma (NSCLC) cells and to facilitate cell migration [12]. Also, dynamin 2 was reported to interact with podocalyxin and regulated cytoskeletal dynamics to promote migration in pancreatic cancer cells [21]. These mechanisms of dynamin-mediated tumor progression are independent of endocytosis.

The detailed molecular mechanisms for the roles of dynamins remain poorly understood, and their role in regulating membrane fission and endocytosis remains controversial [28]. In the present study, dynamin 1 expression was significantly associated with vascular invasion, tumor T stage, and alpha fetoprotein (AFP) levels, which indicated that dynamin 1 might be involved in cell proliferation, cell invasion, and AFP secretion by HCC cells. However, the molecular mechanisms of how dynamin 1 results in the poor patient prognosis in HCC were not identified in this study. However, these molecular mechanisms may rely on cell endocytosis regulation, as liver cells have a strong secretory function.

Although breakthroughs in molecular diagnostics such as next-generation sequencing (NGS) have identified some of the molecular characteristics of HCC, there have been no targeted drugs developed to the most common mutations, and only 25% of tumors possess potentially targetable drivers [29]. Until recently, targeted therapies approved by the US Food and Drug Administration (FDA) have been limited compared to other common cancers, such as lung cancer. More efforts should be made to promote the process of more targeted drugs, which rely on the verification of new biomarkers. The findings from the present study showed that dynamin 1, rather than dynamin 2 or 3, was an independent prognostic factor in patients with HCC. Following the findings from this study, further studies on the function of dynamin 1 in cancer progression may confirm whether dynamin 1 should be included in prognostic immunohistochemistry panels for HCC and other types of cancer.


This study aimed to investigate the expression of dynamin 1, 2, and 3 in tissue sections of human hepatocellular carcinoma (HCC) using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, and to correlate the tissue expression of dynamin proteins and mRNA with clinicopathological factors and overall survival (OS) rates. The findings showed that the upregulation of dynamin 1 at the protein and mRNA level was an independent prognostic biomarker of reduced OS in patients with HCC.


1. Marengo A, Rosso C, Bugianesi E, Liver cancer: Connections with obesity, fatty liver, and cirrhosis: Ann Rev Med, 2016; 67; 103-17

2. Llovet JM, Zucman-Rossi J, Pikarsky E, Hepatocellular carcinoma: Nat Rev Dis Primers, 2016; 2; 16018

3. Zhang W, He H, Zang M, Genetic features of aflatoxin-associated hepatocellular carcinoma: Gastroenterology, 2017; 153; 249-62.e2

4. Kudo M, Finn RS, Qin S, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial: Lancet, 2018; 391; 1163-73

5. Llovet JM, Montal R, Sia D, Finn RS, Molecular therapies and precision medicine for hepatocellular carcinoma: Nat Rev Clin Oncol, 2018; 15; 599-616

6. Zhou YM, Cao L, Li B, Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma: Ann Surg Oncol, 2012; 19; 1700-6

7. Takei K, Slepnev VI, Haucke V, De Camilli P, Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis: Nat Cell Biol, 1999; 1; 33-39

8. Doherty GJ, McMahon HT, Mechanisms of endocytosis: Annu Rev Biochem, 2009; 78; 857-902

9. Srinivasan S, Burckhardt CJ, Bhave M, A noncanonical role for dynamin-1 in regulating early stages of clathrin-mediated endocytosis in non-neuronal cells: PLoS Biol, 2018; 16; e2005377

10. Ferguson SM, De Camilli P, Dynamin, a membrane-remodelling GTPase: Nat Rev Mol Cell Biol, 2012; 13; 75-88

11. Schmid SL, Reciprocal regulation of signaling and endocytosis: Implications for the evolving cancer cell: J Cell Biol, 2017; 216; 2623-32

12. Yamada H, Takeda T, Michiue H, Actin bundling by dynamin 2 and cortactin is implicated in cell migration by stabilizing filopodia in human non-small cell lung carcinoma cells: Int J Oncol, 2016; 49; 877-86

13. Raja SA, Shah STA, Tariq A, Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer: Oncol Lett, 2019; 18; 219-26

14. Khan I, Gril B, Steeg PS, Metastasis suppressors NME1 and NME2 promote dynamin 2 oligomerization and regulate tumor cell endocytosis, motility, and metastasis: Cancer Res, 2019; 79; 4689-702

15. Chen PH, Bendris N, Hsiao YJ, Crosstalk between CLCb/Dyn1-mediated adaptive clathrin-mediated endocytosis and epidermal growth factor receptor signaling increases metastasis: Dev Cell, 2017; 40; 278-88

16. Xu YF, Yang XQ, Lu XF, Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma: Biochem Biophys Res Commun, 2014; 446; 54-60

17. Guo S, Liu HD, Liu YF, Hepatoma-derived growth factor: A novel prognostic biomarker in intrahepatic cholangiocarcinoma: Tumour Biol, 2015; 36; 353-64

18. Xu YF, Liu ZL, Pan C, HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium: Oncogene, 2019; 38; 868-80

19. Sun R, Liu Z, Qiu B, Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway: EBioMedicine, 2019; 47; 142-55

20. Chernikova SB, Nguyen RB, Truong JT, Dynamin impacts homology-directed repair and breast cancer response to chemotherapy: J Clin Invest, 2018; 128; 5307-21

21. Wong BS, Shea DJ, Mistriotis P, A direct podocalyxin-dynamin-2 interaction regulates cytoskeletal dynamics to promote migration and metastasis in pancreatic cancer cells: Cancer Res, 2019; 79; 2878-91

22. Sun X, Cao H, Zhan L, Mitochondrial fission promotes cell migration by Ca(2+)/CaMKII/ERK/FAK pathway in hepatocellular carcinoma: Liver Int, 2018; 38; 1263-72

23. Inokawa Y, Nomoto S, Hishida M, Dynamin 3: A new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis: Onco Targets Ther, 2013; 6; 1417-24

24. Zhang Z, Chen C, Guo W, DNM3 attenuates hepatocellular carcinoma growth by activating P53: Med Sci Monit, 2016; 22; 197-205

25. Gong C, Zhang J, Zhang L, Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma: Am J Cancer Res, 2015; 5; 702-13

26. Cao H, Garcia F, McNiven MA, Differential distribution of dynamin isoforms in mammalian cells: Mol Biol Cell, 1998; 9; 2595-609

27. He C, Zheng S, Luo Y, Wang B, Exosome theranostics: Biology and translational medicine: Theranostics, 2018; 8; 237-55

28. Campelo F, Malhotra V, Membrane fission: The biogenesis of transport carriers: Annu Rev Biochem, 2012; 81; 407-27

29. Allaire M, Nault JC, Molecular targets for HCC and future treatments: J Hepatol, 2017; 66; 234-35


24 November 2022 : Clinical Research  

A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...

Med Sci Monit In Press; DOI: 10.12659/MSM.938665  

01 November 2022 : Clinical Research  

Questionnaire-Based Study of 81 Patients in Poland to Evaluate the Course of Inflammatory Bowel Disease and...

Med Sci Monit 2022; 28:e938243

03 October 2022 : Clinical Research  

Effect of Vitamin D Concentration on Course of COVID-19

Med Sci Monit 2022; 28:e937741

In Press

25 Nov 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

Med Sci Monit In Press; DOI: 10.12659/MSM.937990  

24 Nov 2022 : Clinical Research  

Effect of Positive End-Expiratory Pressure (PEEP) Titration in Elderly Patients Undergoing Lobectomy

Med Sci Monit In Press; DOI: 10.12659/MSM.938225  

24 Nov 2022 : Clinical Research  

A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...

Med Sci Monit In Press; DOI: 10.12659/MSM.938665  

22 Nov 2022 : Clinical Research  

Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative...

Med Sci Monit In Press; DOI: 10.12659/MSM.938412  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750